The estimated Net Worth of Tornout Jan M Van is at least $3.05 ezer dollars as of 17 February 2022. Dr Van owns over 7,022 units of Tyme Technologies Inc stock worth over $3,048 and over the last 4 years he sold TYME stock worth over $0.
Dr has made over 3 trades of the Tyme Technologies Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he bought 7,022 units of TYME stock worth $2,528 on 17 February 2022.
The largest trade he's ever made was buying 7,022 units of Tyme Technologies Inc stock on 17 February 2022 worth over $2,528. On average, Dr trades about 1,966 units every 64 days since 2021. As of 17 February 2022 he still owns at least 9,831 units of Tyme Technologies Inc stock.
You can see the complete history of Dr Van stock trades at the bottom of the page.
Dr. Jan Marie-Albert Van Tornout M.D., M.Sc. is the Acting Chief Medical Officer at Tyme Technologies Inc.
Dr Sc is 65, he's been the Acting Chief Medical Officer of Tyme Technologies Inc since . There are 4 older and 14 younger executives at Tyme Technologies Inc. The oldest executive at Tyme Technologies Inc is Gerald Sokol, 77, who is the Independent Director.
Tornout's mailing address filed with the SEC is C/O TYME TECHNOLOGIES, INC., 1 PLUCKEMIN WAY - SUITE 103, BEDMINSTER, NJ, 07921.
Over the last 7 years, insiders at Tyme Technologies Inc have traded over $11,656,990 worth of Tyme Technologies Inc stock and bought 384,831 units worth $412,502 . The most active insiders traders include Steve Hoffman, Michael Demurjian és Douglas A Michels. On average, Tyme Technologies Inc executives and independent directors trade stock every 8 days with the average trade being worth of $15,104. The most recent stock trade was executed by Michael Demurjian on 6 September 2022, trading 160,000 units of TYME stock currently worth $40,000.
Tyme Technologies, Inc., is an emerging biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company's therapeutic approach is designed to take advantage of a cancer cell's innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body's natural immune system.
With the development of TYME-18 and TYME-19, the Company believes that it is also emerging as a leader in the development of bile acids as potential therapies for cancer and COVID-19.
Tyme Technologies Inc executives and other stock owners filed with the SEC include: